ReviewCurrent topics in medicinal chemistry2026
A Structure-activity Relationship (SAR) Insight for the Most Effective Oral Antidiabetic Compounds-A Current Review.
Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Diabetes mellitus, a chronic metabolic disorder, poses a significant global health challenge, demanding continuous research into effective treatments. With projections of 629 million individuals affected by 2045 and escalating healthcare costs, the need for new anti-diabetic medications is urgent. Current therapies often present limitations, including undesirable side effects and insufficient long-term efficacy. This review explores the development of oral anti-diabetic drugs (OADs), focusing on the structure-activity relationship (SAR) employed to create both established and emerging classes of medications. We examine the six major OAD classes: biguanides, sulfonylureas, meglitinides, thiazolidinediones, DPP-4 inhibitors, and SGLT2 inhibitors. In addition, a new promising class of OAD, namely metal complexes, is discussed. This review highlights the crucial role of synthetic chemistry in advancing diabetes treatment and improving patient outcomes.
Indexed as
Identifiers
40814884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.